GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 2005-2009  (10)
  • Medicine  (10)
  • 1
    In: Blood, American Society of Hematology, Vol. 114, No. 22 ( 2009-11-20), p. 1159-1159
    Abstract: Abstract 1159 Poster Board I-181 Background In allogeneic SCT, genetic factors such as donor and recipient gene polymorphisms of pro- and anti-inflammatory cytokines have been associated with the incidence and severity of GVHD. However, the influence of such donor and recipient gene polymorphisms on other outcomes, such as early infection after SCT, has seldom been described. TNFαa, TNF receptorII (TNFRII), IL-10 and TGF gene contain multiple single nucleotide polymorphisms (SNPs) in the promoter and codon region. We thus studied the association of this panel of candidate gene polymorphisms with the incidence of the first episodes of early bacterial infections within 100 days after allo-HSCT. Methods A total of 138 unrelated donor/recipient pairs, who had undergone HLA-matched allo-HSCT from January 2001 to March 2009 at the First Affiliated Hospital of Zhejiang University School of Medicine, were tested for TNFαa(TNFαa-857 C 〉 T, TNFαa-863 C 〉 A, TNFαa-1031 T 〉 C), TNFRII (codon196 T 〉 G), IL-10 (IL10-1082 A 〉 G, IL10-819 T 〉 C, IL10-592 A 〉 C), TGF (TGF-509 T 〉 C, TGF+869 C 〉 T) polymorphism allele frequencies and genotype. SNPs were analysed by Multiplex SnaPshot. We considered the first episodes of early bacterial infections within 100 days after allo-HSCT have developed when sepsis, pneumonia, or septic shock was diagnosed according to previously published criteria. Results (1) 133 patients achieved complete donor chimerism in the peripheral blood and 5 patients had graft failure. All patients achieved an absolute neutrophil count (ANC) greater than 0.5×109/L at day 13 (7∼22) and platelet recovery at day 15 (7∼64). The cumulative incidence of at least one bacterial infection was 47.8% (pneumonia and intestinal infection are the most popular) within 100 days after allo-HSCT. There is no significant difference in the time to neutrophil recovery in patients who experienced early bacterial infections with those who did not (13.6 vs 12.8,P=0.115). (2) The TNFαa-857 C/C genotype and TNFRII 196 T/T genotype of the donor were significantly associated with a higher risk of early bacterial infection ( for TNFαa-857 C/C genotype: 53.3% vs 29.0%, P=0.024 ; TNFRII 196 T/T genotype: 53.5% vs 33.3%, P=0.038); (3) The TGF-509 T/T genotype of the donor was significantly associated with a higher risk of early bacterial infection (62.5% vs 41.8, P=0.038); (4) Transplantation from donors with IL10-819 C/C genotype or IL10-592 C/C genotype were significantly associated with a higher risk of early bacterial infection (for IL10-819 C/C genotype: 71.4.1% vs 45.3%, P=0.034; IL10-592 C/C genotype: 70.0.1% vs 45.8%, P=0.055); (5) The genotypes of TNFαa-863, TNFαa-1031, IL10-1082 and TGF+869 were not found to be associated with the risk of early bacterial infection. Conclusions Recent studies have shown that the generation potential of IL-10 is influenced by the polymorphism of the IL-10 gene. The IL10-819*C allele and IL10-592 *C allele are associated with higher secretion of IL-10 than IL10-819*T allele and IL10-592*A allele. In our data, a higher risk of early bacterial infection with IL10-819 C/C and IL10-592 C/C genotype was postulated to be associated with a higher IL-10 production, which suppressed reactive T-cell response. These results, which is the first report of TNFαa, TNFRII, IL-10and TGF polymorphic features of Chinese population with the risk of early bacterial infection after HLA-matched unrelated allo-HSCT, suggest an interaction of the donor TNFαa-857C/C, TNFRII 196 T/T, IL10-819 C/C, IL10-592 C/C and TGF-509 T/T genotypes on risk of early infection. These results are helpful for predict allo-HSCT outcome, identify more suitable donors and clarify therapy on an individual patient basis. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2009
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: The Journal of Immunology, The American Association of Immunologists, Vol. 178, No. 4 ( 2007-02-15), p. 2229-2240
    Abstract: IL-19, IL-20, IL-22, IL-24, and IL-26 are members of the IL-10 family of cytokines that have been shown to be up-regulated in psoriatic skin. Contrary to IL-10, these cytokines signal using receptor complex R1 subunits that are preferentially expressed on cells of epithelial origin; thus, we henceforth refer to them as the IL-20 subfamily cytokines. In this study, we show that primary human keratinocytes (KCs) express receptors for these cytokines and that IL-19, IL-20, IL-22, and IL-24 induce acanthosis in reconstituted human epidermis (RHE) in a dose-dependent manner. These cytokines also induce expression of the psoriasis-associated protein S100A7 and keratin 16 in RHE and cause persistent activation of Stat3 with nuclear localization. IL-22 had the most pronounced effects on KC proliferation and on the differentiation of KCs in RHE, inducing a decrease in the granular cell layer (hypogranulosis). Furthermore, gene expression analysis performed on cultured RHE treated with these cytokines showed that IL-19, IL-20, IL-22, and IL-24 regulate many of these same genes to variable degrees, inducing a gene expression profile consistent with inflammatory responses, wound healing re-epithelialization, and altered differentiation. Many of these genes have also been found to be up-regulated in psoriatic skin, including several chemokines, β-defensins, S100 family proteins, and kallikreins. These results confirm that IL-20 subfamily cytokines are important regulators of epidermal KC biology with potentially pivotal roles in the immunopathology of psoriasis.
    Type of Medium: Online Resource
    ISSN: 0022-1767 , 1550-6606
    RVK:
    RVK:
    Language: English
    Publisher: The American Association of Immunologists
    Publication Date: 2007
    detail.hit.zdb_id: 1475085-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Blood, American Society of Hematology, Vol. 110, No. 11 ( 2007-11-16), p. 4827-4827
    Abstract: Background: Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (MM) with an overall response rate of 92% and a CR rate of 18% (Alexanian et al, Hematology12(3):235–239, 2007), but this regimen has not been reported in Chinese patients. We now report our experience with this combination. Objectives: To investigate the efficacy and safety of bortezomib in combination of dexamethasone plus subsequent thalidomide as primary treatment for MM. Patients and Method: Between June 2006 and August 2007, 11 consecutive newly-diagnosed patients with symptomatic MM were treated with bortezomib at 1.3 mg/m2 IV on days 1, 4, 8 and 11, dexamethasone at 20 mg/m2 IV daily on the day of bortezomib and the day after. All patients received daily oral thalidomide that was escalated from 100 mg to 200 mg. Seven of 11 patients were male and 4 were female. Median age was 57 years (range 47–86). Seven of 11 patients were stage 2 according to the International Staging System, 4 out of 11 patients were stage 3. Eleven patients received a median of 2 cycles of therapy (range 1–6). The Blade criteria were used for response evaluation. Toxicities were evaluated according to the NCI Common Toxicity Criteria version 3. Results: Nine out of 11 patients (82%) achieved PR and 2 (18%) achieved CR; therefore the overall response rate was 100%. With a median follow-up duration of 5 months (1– 14 months), no patients died. Grade 3–4 toxicities included fatigue (3/11), thrombocytopenia (3/11), diarrhea (3/11) and orthostatic hypotension (2/11). Grade 2 neuropathy occurred in 3 out of 11 patients, herpes zoster occurred in 3 out of 11 patients. Routine anticoagulation or anti-thrombosis was not used. There was no DVT/PE in 11 patients. Conclusion: Our preliminary experience indicated that bortezomib-dexamethasone-thalidomide is highly effective in newly-diagnosed MM. Grade 3 and 4 toxicities were rare after median 2 cycles of therapy. The relative lower rates of neuropathy and DVT/PE in this report with Chinese MM patients are being cautiously observed.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2007
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: International Journal of Cancer, Wiley, Vol. 125, No. 12 ( 2009-12-15), p. 2844-2853
    Type of Medium: Online Resource
    ISSN: 0020-7136 , 1097-0215
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2009
    detail.hit.zdb_id: 218257-9
    detail.hit.zdb_id: 1474822-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 112, No. 11 ( 2008-11-16), p. 4417-4417
    Abstract: Allogeneic hematopoietic stem cell transplantation (alloSCT) is nowadays most frequently applied in patients with acute myeloid leukemia (AML), and it effectively reduces the relapse as its stronger graft-versus-leukemia (GVL) effect, however, the appropriate role and timing of alloSCT in AML are poorly defined. We retrospectively investigated the outcomes of unrelated donor hematopoietic stem cell transplantation (URD-HSCT, n=51; 44 in CR1, 7 beyond CR1) and sibling donor BMT (Sib-HSCT, n=31; 24 in CR1, 7 beyond CR1) for AML between April 1999 and April 2008. The median age of all patients was 27.5 years (range 12–49 years), and HLA high-resolution typing was used for donor-recipient matching with 35 cases of HLA-matched and 16 cases of HLA 1–2 alleles mismatched in URD-HSCT group, while 28 cases of HLA-matched and 3 cases of HLA 1–2 alleles mismatched in Sib-HSCT group. All of the patients were received Bu/Cy or Bu/Cy modified myeloablative conditionging regimen. Mycophenolate mofetil (MMF) combined with CsA and short course MTX were performed to prevent aGVHD and 4 patients in unrelated donor transplant group received additional anti-CD25 monoclonal antibody to prevent severe aGVHD. Hemopoietic recovery and was observed in all patients and the median time to achieve ANC & gt;0.5×109/L was 12.5 days (range 7–22 days), platelets & gt;20×109/L was 15 days (range 9–144 days), and engraftment of neutrophil and platelet did not differ between the two transplant groups. The incidence of aGVHD was significantly higher in URD-HSCT group (54.9% vs 19.4%, p & lt;0.001), however, there was no different of severe aGVHD (13.7% vs 3.2%, p & gt;0.05) and transplant-related mortality (11.8% vs 3.2%, p & gt;0.05) at 100 days between URD-HSCT and Sib-HSCT groups. With a median follow-up of 16.2 months, the 3 years overall survival of the total patients was 73.90±5.11%, and there were no different of disease free survival between AML patients in CR1 and beyond CR1 (69.12% vs 64.29%, p & gt;0.05). Relapse occurred in 15.7% and 9.7% patients following unrelated and sibling donors transplantation respectively, and 3 years disease free survival were 63.85±6.85% and 79.55±7.48% respectively (p & gt;0.05). Based on the data, alloSCT provides a better prospect for cure and would be mostly recommended for patients with AML either in CR1 or beyond CR1, which could be able to improve the leukemia free survival. The outcome of unrelated donor transplantation is comparable to that of sibling donor transplantation for AML. Unrelated donor should be considered in AML patients without a proper sibling donor, especially to patients with unfavorable cytogenetics. MMF combined with CsA and MTX could prevent severe aGVHD efficiently which would reduce the transplant-related mortality in URD-HSCT. At the same time, modifications of supportive care and preparative regimens continue to improve results and extend the application of alloSCT in AML.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2008
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    American Society of Hematology ; 2006
    In:  Blood Vol. 108, No. 11 ( 2006-11-16), p. 3867-3867
    In: Blood, American Society of Hematology, Vol. 108, No. 11 ( 2006-11-16), p. 3867-3867
    Abstract: The patients with malignant hematopathy are the high-risk group of invasive fungal infections (IFI). Candidemia and IFI caused by Candidas in patients with a hematological malignancy are common but Candida arthritis is rare. Here, we reported a case of Candida tropicalis arthritis of the knee that occurred with acute monocytic leukemia during the recovery period of post chemotherapy myelosuppression and agranulocytosis. Case report: A 45-year-old Chinese woman was diagnosed with acute monocytic leukemia with normal caryotype in november 2004. Complete remission was achieved upon completion of 2 courses of induction chemotherapy. Treatment was administered via a Hickman catheter in the left elbow. Two days after phase V consolidation chemotherapy, the patient experienced high fever accompanied by the development of arthritis in the right knee. The diagnosis of Candida tropicalis arthritis of the knee was confirmed by the appearance of Candida tropicalis isolated from the synovial fluid, but no leukemic cells and acid-fast bacilli were found. According to the susceptibility test in vitro, itraconazole and amphotericin B injection were used sequentially for therapy for 4–5 weeks, which effectively inhibited bacterial growth. However, the arthritis relapsed after 4–6 weeks of drug withdrawal. The arthritis was fully resolved after 8 weeks of therapy with fluconazol injection at a dose of 400mg/d and douching articular cavity with amphotericin B once a week. And then sequential therapy with oral fluconazole was commenced. There was no any adverse effect occurrence during the course of treatment. Discussion: Although Candida arthritis in patient with a hematological malignancy is rare, it still occurred in patient with hypoimmunity. Early diagnosis is difficult due to no distinctive clinical manifestation and hysteresis of pathogenic organism detection. It was found that the knee was the sole joint affected according to the review of fourteen other reports of Candida arthritis in patients with a hematological malignancy but the reason remains unclear. Fungal arthritis must be taken into consideration when dealing with patients with immune deficiency accompanied by arthritis, especially gonarthritis. We emphasize that the most important factors for the successful treatment of fungal arthritis are identified diagnosis and adequate dosage through out the course of treatment.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2006
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    American Society of Hematology ; 2005
    In:  Blood Vol. 106, No. 11 ( 2005-11-16), p. 4917-4917
    In: Blood, American Society of Hematology, Vol. 106, No. 11 ( 2005-11-16), p. 4917-4917
    Abstract: The endoplasmic reticulum (ER) is the major organelle for protein synthesis and maturation as well as the regulation of intracellular calcium (Ca2+) homeostasis. The accumulation of unfolded proteins in the ER lumen or depletion of Ca2+ from the ER lumen leads to the ER stress response known as unfold protein response. This response enhances the ability of protein folding by inducing ER resident chaperones such as glucose-regulated stress protein 78 or immunoglobulin heavy-chain binding protein (GRP78/BIP) mRNA and protects the cell from ER stress by splicing of X-box binding protein 1 (XBP-1) mRNA, and synthesis of phosphatidylcholine, the primary phospholipid of the ER membrane. However, when the ER function is severely impaired, the organelle elicits apoptotic signals. One of the components of the ER stress-mediated apoptosis pathway is C/EBP homologous protein (CHOP), also known as growth arrest- and DNA damage-inducible gene 153. Homoharringtonine (HHT), one of the alkaloids from a Chinese natural plant, Cephalotaxus, has currently been used successfully in the treatment of acute and chronic myeloid leukemias and has been shown to induce apoptosis of different types of leukemic cells in vitro. But the mechanism of how HHT causes apoptosis remains unknown. In this study, we investigated the relationship between ER stress and apoptosis of MUTZ-1 cells (cell line of MDS) treated with HHT. HHT induced growth inhibition of MUTZ-1 cells was measured by MTT method. Apoptosis was detected by FACS and observed by light and electron microscopy. Concentration of cystosolic calcium was measured with the spectrofluorometer. The mRNA expression level of CHOP, BIP and XBP1 was detected by semi-quantitative RT-PCR. We found that after exposure of MUTZ-1 to HHT (rang 0.02~0.4ug/ml) for 24 to 72 hours, the IC50 and the percentage of apoptotic MUTZ-1 cells increased in a time and dose dependent manner. Typical apoptotic cells and release of Ca2+ from the cytosolic Ca2+ storage were observed. RT-PCR analysis revealed that mRNAs for ER stress-associated proapoptotic factor CHOP and an ER chaperone BiP, XBP1 are markedly increased at 4 hours after 0.05ug/ml HHT treated and reach the top level at 12hours, then decreased to the level before treatment at 24 hours. Induction of ER stress-responsive proteins (BIP and CHOP) was also observed at 12 hours. These results indicate that HHT could not only inhibit MUTZ-1 growth but also induce MUTZ-1 apoptosis and HHT-induced MUTZ-1 cell death is likely mediated by the ER stress pathway.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2005
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    Wiley ; 2009
    In:  International Journal of Cancer Vol. 124, No. 12 ( 2009-06-15), p. 2886-2892
    In: International Journal of Cancer, Wiley, Vol. 124, No. 12 ( 2009-06-15), p. 2886-2892
    Abstract: Hepatitis C virus (HCV) infection is often associated with chronic liver disease, which is a major risk factor for the development of hepatocellular carcinoma (HCC). To study the HCV host‐cell relationship on the molecular level, HepG2 and Huh7 cells were stably transfected with an infectious cDNA clone of HCV or with empty vector. Evidence for HCV replication was obtained in both culture systems. HCV also stimulated growth in vitro . To identify genes whose altered expression by HCV are important to the pathogenesis of infection, RNAs were isolated from HepG2‐HCV and HepG2‐vector cells and subjected to microarray analysis. The results showed that arginase 1 mRNA and protein were elevated about threefold in HCV positive compared with negative cells ( p 〈 0.01). Arginase 1 expression was elevated in more than 75% of HCV infected liver samples compared with paired HCC from the same patients ( 〉 33% positive) and to uninfected liver tissues (0% positive). Arginase 1 specific siRNA inhibited the ability of HCV to stimulate hepatocellular growth in culture by 〉 70%, suggesting that the metabolism of arginine to ornithine may contribute to HCV mediated stimulation of hepatocellular growth. Introduction of arginase specific siRNA also resulted in increased nitric oxide synthase (iNOS) ( 〉 1.2‐fold), nitric oxide (NO) production ( 〉 3‐fold) and increased cell death ( 〉 2.5‐fold) in HCV positive compared with negative cells, suggesting that these molecules potentially contribute to hepatocellular damage. Hence, an important part of the mechanism whereby HCV regulates hepatocellular growth and survival may be through altering arginine metabolism. © 2009 UICC
    Type of Medium: Online Resource
    ISSN: 0020-7136 , 1097-0215
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2009
    detail.hit.zdb_id: 218257-9
    detail.hit.zdb_id: 1474822-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Movement Disorders, Wiley, Vol. 24, No. 13 ( 2009-10-15), p. 1902-1905
    Type of Medium: Online Resource
    ISSN: 0885-3185
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2009
    detail.hit.zdb_id: 2041249-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Clinical Immunology, Elsevier BV, Vol. 123 ( 2007), p. S62-
    Type of Medium: Online Resource
    ISSN: 1521-6616
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2007
    detail.hit.zdb_id: 1462862-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...